Healthcare | January 09, 2026
Leeford Healthcare bets Rs. 200 crore on orthopedic & mobility aids
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Subscribe To Our Newsletter & Stay Updated
